StockData

Akebia Therapeutics vs Travere Therapeutics

AKBA and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AKBA and TVTX compare

Travere Therapeutics is the larger company, worth 38 times as much as Akebia Therapeutics ($4.7B against $124M).

Travere Therapeutics grew revenue faster over the last twelve months (77.1% versus 7.5% for Akebia Therapeutics).

Travere Therapeutics keeps more of each dollar of sales as profit, with a net margin of −7.4% compared with −13.5% at Akebia Therapeutics.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAKBATVTX
Size and price
Market cap$124M$4.7B
Share price$0.449$49.70
Change, 1 year−74.5%46.7%
Change, 5 years−83.2%71.2%
Beta (5Y)1.051.95
Employees194497
StockData Score
Total score66
Valuation score00
Growth score23 (better)
Performance score22
Health score2 (better)1
Dividend score00
Valuation
P/S0.6× (better)7.9×
P/B5.0× (better)191×
EV/EBITDA–192×
P/FCF3.1×–
FCF yield32.4%–
Fair value–$6.04
Margin of safety–−723%
Growth
Revenue growth (TTM)7.5%77.1% (better)
Revenue growth, 5Y average−4.3%19.9% (better)
Profitability
Gross margin79.6%98.6% (better)
Operating margin−6.9%−6.8% (better)
Net margin−13.5%−7.4% (better)
FCF margin18.4%–
Return on equity−109% (better)−152%
Financial health
Debt / equity1.98–
Interest coverage–−4.3×
Current ratio1.434.05 (better)
Altman Z-score−5.862.19 (better)
Piotroski F-score77
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions39.7%112%
Held by insiders2.9%1.6%
Insider net buying, 12 months−$876K (better)−$110M
Short interest, % of float10.1%10.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.